Abbott Laboratories agreed to pay Galapagos as much as $1.35 billion for rights to an experimental rheumatoid arthritis drug that would compete with a Pfizer pill.
Abbott to buy Galapagos arthritis-drug rights for up to $1.35 billion
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.